

REPLY TO:
SPRING HOUSE TECHNICAL CENTER
727 NORRISTOWN ROAD
P.O. BOX 904
SPRING HOUSE, PA 15477-0904
(215) 641-7000



May 16, 2002

Dear Former Spring House Employee and/or Family Member:

The purpose of this letter is to inform you that Rohm and Haas Company will begin an epidemiological study involving current and former Spring House Technical Center employees.

Over the past 40 years, since the facility opened in 1963, there have been 10 reported cases of brain cancer among approximately 6,000 employees of the Spring House site. That is approximately twice the number that would be expected compared with the general population of the U.S. Rohm and Haas Company is interested in learning more about what caused these cancers and what, if any, associations with workplace chemicals can be found. A thorough epidemiological study will be undertaken with the results and findings published in a peer-reviewed publication. The study will begin in June, 2002 and is expected to take about 15-18 months to complete.

We believe the Spring House site is a safe workplace. The company believes the study is prudent and appropriate based on concerns expressed by several employees about longtime Spring House colleagues and a study of excess brain cancer among employees at an Amoco research facility in Illinois.

While we don't know the specifics of these cancers, we are concerned and want to know if there are any other cases, if the cancers are related and what, if any, workplace relationship they may have, including what chemicals or risk factors may be involved.

Dr. Arvind Carpenter, the company's Director of Epidemiology, will conduct a case-control study and keep current and former employees apprised as the study progresses.

We will hold information meetings at our Spring House Technical Center in order to present the outline of the study and to answer any questions you may have. We will host two information sessions on Monday, June 3, 2002 - one at noon and a second at 6:30 PM. For those not able to attend either of the June 3 meetings, we will hold another session on, Monday, June 17, 2002 at 6:30 PM. Refreshments will be served at the evening meetings. These meetings will be held in the Main Conference Room in Building 6 at the Spring House site. If you plan to attend any of these meetings, please call (215) 641-7896 to RSVP so that we know approximately how many people to expect for the meetings.

In the meantime, if you have any questions or know of other colleagues who may have been diagnosed with brain cancer, please feel free to contact Dr. Jeffrey Erinoff, Spring House Medical Director, at (215) 619-5351 or via email at: jerinoff@rohmmaas.com.

Sincerely,

Eileen M. Bonner, M.D., M.P.H.
Director, Corporate Medical Services

REPLY TO:
SPRING HOUSE TECHNICAL CENTER
727 NORRISTOWN ROAD
P.O. BOX 904
SPRING HOUSE, PA 19477-0904
(215) 641-7000



October 6, 2003

Re: Status Update on Spring House Epidemiological Study

Dear Former Spring House Employee:

At our information meetings with current and former Spring House employees last year and early this year about the brain cancer epidemiological study, we said we would be giving you an update before the study's completion, scheduled for December, 2003.

The purpose of this letter is to provide an update as to the study's progress and next steps.

Study Participants, the Work Exposure Assessment Process and Progress to Date

The investigation underway is called an epidemiological case-control study. It includes all known current and former Spring House employees with brain cancer matched with employees with similar backgrounds of age, date of hire, race and gender who do not have brain cancer.

The study team is now completing the work exposure assessment process. Work histories for the study's participants are categorized by site, department and job title. The work exposure assessment involves a detailed examination of relevant documents relating to the study participants' work histories—B-reports, notebooks and technical reports. This is done in order to review and assess projects worked on by the individual, noting chemicals used, their conditions and applications.

This is a difficult and complicated process. It includes assembling and categorizing the list of chemicals and physical agents handled by each of the study's participants while working at the site. This process is now 80% complete. The study remains on track for completion by the end of this year.

Next Steps: Data Analysis and Review by Outside Advisory Panel

After all study tasks are completed, we will begin the process of analyzing all the data. This should occur starting later this month and early November, 2003. When the analysis is completed, these results will be reviewed by an outside advisory panel.

The outside advisory panel consists of three prominent epidemiology and industrial health experts with extensive experience and knowledge of brain cancer epidemiological studies.

REPLY TO:
SPRING HOUSE TECHNICAL CENTER
727 NORRISTOWN ROAD
P.O. BOX 904
SPRING HOUSE, PA 19477-0904
(215) 641-7000



May 16, 2002

Dear Former Spring House Employee and/or Family Member:

The purpose of this letter is to inform you that Rohm and Haas Company will begin an epidemiological study involving current and former Spring House Technical Center employees.

Over the past 40 years, since the facility opened in 1963, there have been 10 reported cases of brain cancer among approximately 6,000 employees of the Spring House site. That is approximately twice the number that would be expected compared with the general population of the U.S. Rohm and Haas Company is interested in learning more about what caused these cancers and what, if any, associations with workplace chemicals can be found. A thorough epidemiological study will be undertaken with the results and findings published in a peer-reviewed publication. The study will begin in June, 2002 and is expected to take about 15-18 months to complete.

We believe the Spring House site is a safe workplace. The company believes the study is prudent and appropriate based on concerns expressed by several employees about longtime Spring House colleagues and a study of excess brain cancer among employees at an Amoco research facility in Illinois.

While we don't know the specifics of these cancers, we are concerned and want to know if there are any other cases, if the cancers are related and what, if any, workplace relationship they may have, including what chemicals or risk factors may be involved.

Dr. Arvind Carpenter, the company's Director of Epidemiology, will conduct a case-control study and keep current and former employees apprised as the study progresses.

We will hold information meetings at our Spring House Technical Center in order to present the outline of the study and to answer any questions you may have. We will host two information sessions on Monday, June 3, 2002 – one at noon and a second at 6:30 PM. For those not able to attend either of the June 3 meetings, we will hold another session on, Monday, June 17, 2002 at 6:30 PM. Refreshments will be served at the evening meetings. These meetings will be held in the Main Conference Room in Building 6 at the Spring House site. If you plan to attend any of these meetings, please call (215) 641-7896 to RSVP so that we know approximately how many people to expect for the meetings.

In the meantime, if you have any questions or know of other colleagues who may have been diagnosed with brain cancer, please feel free to contact Dr. Jeffrey Erinoff, Spring House Medical Director, at (215) 619-5351 or via email at: jerinoff@rohmmaas.com.

Sincerely,

Eileen M. Bonner, M.D., M.P.H.
Director, Corporate Medical Services

REPLY TO:
SPRING HOUSE TECHNICAL CENTER
727 NORRISTOWN ROAD
P.O. BOX 904
SPRING HOUSE, PA 19477-0904
(215) 641-7000



October 6, 2003

Re: Status Update on Spring House Epidemiological Study

Dear Former Spring House Employee:

At our information meetings with current and former Spring House employees last year and early this year about the brain cancer epidemiological study, we said we would be giving you an update before the study's completion, scheduled for December, 2003.

The purpose of this letter is to provide an update as to the study's progress and next steps.

Study Participants, the Work Exposure Assessment Process and Progress to Date

The investigation underway is called an epidemiological case-control study. It includes all known current and former Spring House employees with brain cancer matched with employees with similar backgrounds of age, date of hire, race and gender who do not have brain cancer.

The study team is now completing the work exposure assessment process. Work histories for the study's participants are categorized by site, department and job title. The work exposure assessment involves a detailed examination of relevant documents relating to the study participants' work histories—B-reports, notebooks and technical reports. This is done in order to review and assess projects worked on by the individual, noting chemicals used, their conditions and applications.

This is a difficult and complicated process. It includes assembling and categorizing the list of chemicals and physical agents handled by each of the study's participants while working at the site. This process is now 80% complete. The study remains on track for completion by the end of this year.

Next Steps: Data Analysis and Review by Outside Advisory Panel

After all study tasks are completed, we will begin the process of analyzing all the data. This should occur starting later this month and early November, 2003. When the analysis is completed, these results will be reviewed by an outside advisory panel.

The outside advisory panel consists of three prominent epidemiology and industrial health experts with extensive experience and knowledge of brain cancer epidemiological studies.

The outside advisory panel members include Dr. Peter Lees, Professor of Industrial Hygiene, The Johns Hopkins School of Public Health, Dr. Elizabeth Ward, Senior Epidemiologist, the American Cancer Society and Dr. Dana Flanders, Professor of Epidemiology and Professor of Biostatistics, Rollins School of Public Health, Emory University.

Dr. Lees was a member of the investigative study team for the BP Amoco study of brain cancer among research scientists. Dr. Ward served for 20 years as an epidemiologist for the National Institute for Occupational Safety and Health. Dr. Flanders has published over 54 articles on health services research and health care. We have recently met with the advisory panel and reviewed our progress to date.

Final Results Announcement, December, 2003

Final results of the Spring House brain cancer study will be announced in late December, first to current and former Spring House employees, and afterward to the public. The announcement meetings will take place at Spring House and include Dr. Carpenter and the outside advisory panel.

As part of the study process, the final results will then be incorporated into a report for submission and publication in a peer-reviewed journal, scheduled for the first quarter of 2004.


If You Have Questions

In the meantime, if you have questions relating to the study or information relating to individuals who worked at Spring House who may have brain cancer, please contact Dr. Jeff Erinoff, Spring House Medical Director, at 215-641 5351. Dr. Erinoff can also be reached through e-mail at: jerinoff@rohmmaas.com or via US Mail at the following address:

Dr. Jeffrey Erinoff, Medical Director
Rohm and Haas Company
Spring House Technical Center
Box 904
727 Norristown Road
Spring House, PA 19477-0904

We will be in touch with you in the next two months regarding the study results and information meeting date.

Sincerely,



David E. Greenley, Ph.D.
Director of Technology Operations
Site Manager, Spring House Technical Center

REPLY TO:
SPRING HOUSE TECHNICAL CENTER
727 NORRISTOWN ROAD
P.O. BOX 904
SPRING HOUSE, PA 19477-0904
(215) 641-7000



December 10, 2003

Dear Former Spring House Employee:

As you may know, the company over the past 18 months has been conducting an epidemiological investigation of brain cancer at our Spring House Technical Center.

The purpose of this letter is to let you know that the epidemiological investigation has been completed and the findings will be announced by Dr. Arvind Carpenter on Thursday, January 8, 2004 at our Spring House Technical Center Emmons Auditorium at 6 p.m.

The meeting will review the purpose of the study, how it was conducted and the results and what they mean. The presentation portion will last about 45 minutes and allow time for questions. Also present will be members of the outside Advisory Panel of experts in epidemiology and industrial hygiene, who advised the Rohm and Haas epidemiological study team and reviewed the progress. They will also be available for comments and questions.

We could not hold these meetings in December because all three members of the outside Advisory Panel were not available to attend at that time.

If you have any questions in the meantime, please contact Dr. Jeffrey Erinoff at 215-619-5351.

Thank you.

A handwritten signature in black ink, appearing to read "D. Greenley". The signature is fluid and cursive.

Dave Greenley
Director, Technology Operations
Site Manager

REPLY TO:
SPRING HOUSE TECHNICAL CENTER
727 NORRISTOWN ROAD
P.O. BOX 904
SPRING HOUSE, PA 19477-0904
(215) 641-7000



January 8, 2004

Dear Current and Former Spring House Employee:

The executive summary below represents an important milestone in the 18-month investigation at the Spring House Technical Center to address excess brain cancers among current and past employees of the facility since it opened in 1963.

These summary results, provided by the Rohm and Haas epidemiological study team and reviewed by an outside advisory panel of experts in epidemiology and industrial hygiene, were commissioned in 2002 to help us understand the incidence of brain tumors among Spring House employees and to determine what, if any, correlation they had to workplace chemicals.

Study Scope and Methodology

The case-control study involved 12 individuals who had developed primary malignant brain cancers, 3 individuals who had developed benign tumors and selected controls, persons who did not have the disease. The controls were matched with cases on the date of birth, date of hire at Rohm and Haas, race and gender. These included individuals originally identified as having brain tumors and those identified from other sources. The study included 5 Glioblastoma Multiforme cases, 2 Astrocytoma Grade II cases and 5 brain cancers with no cell type available from the records. The 3 benign tumors were identified as 2 Meningiomas and 1 Accoustic Neuroma. Work exposure assessments and analysis were completed for the 12 individuals with primary malignant brain cancers as well as the 3 benign tumor cases.

The study used a variety of information-gathering sources and data, including work history, occupation, department, job title, building location(s), medical history, non-work related exposures, and lifestyle information, such as smoking and alcohol use. This was done in order to construct an exposure assessment for comparison between the brain cancer cases and controls. Other sources reviewed for exposure assessment were B-reports, scientific notebooks and technical and research reports both for cases and controls. The Exposure Assessment Team members were blind to the status of cases or controls to avoid bias.

As part of this process, over 2000 documents were reviewed, including over 100 B-reports, 500 notebooks and 1400 technical reports. Over 20,000 individual chemicals were identified and then sorted into 36 categories.

A statistical analysis determined correlations between chemicals, cases and controls to examine possible risk factors including:

- exposure to a specific category of chemicals;
- potential exposure to any chemical linked to cancer in the scientific literature (82 were identified);
- potential exposure to chemicals associated with specific businesses in Rohm and Haas, such as leather, ion exchange, biocides and agricultural chemicals.
- potential exposure to ionizing radiation
- potential effect of specific laboratory and building locations

The study design, exposure assessment, analytic techniques and data findings were reviewed by the outside advisory panel, consisting of Dr. Peter Lees, Professor of Industrial Hygiene at the Johns Hopkins School of Public Health and a member of the Amoco Research Center brain cancer epidemiological study, Dr. Elizabeth Ward, Senior Epidemiologist, the American Cancer Society, formerly with the National Institute of Occupational Safety and Health (NIOSH), and Dr. Dana Flanders, Professor of Epidemiology and Professor of Biostatistics at the Rollins School of Public Health, Emory University.

The study will be the basis of a scientific paper that Rohm and Haas will submit for publication in a peer-reviewed journal later this year.

Findings

The study found no risk factor emerging as statistically significant as an association with the occurrence of brain cancer or benign brain tumors.

In the analysis of building location, several of the individuals with brain cancer worked on similar projects and in the same building at one time during their careers, but did not show a statistical significance compared with the control population.

Next Steps

We have not identified a specific cause or causes for the brain cancer cases identified in the study. While the study findings show no significant association with workplace chemicals, we also understand the concern and frustration of some in not clearly being able to link the brain cancer cases with a specific cause or to determine if or why the number of brain cancers is elevated. We will, however, begin a study of all deaths of Spring House employees, called a cohort mortality study. That will provide additional understanding of whether the number of brain cancer cases is actually higher among the approximately 6,000 Spring House employees who ever worked at the site and the general U.S. population as well as what, if any other cancer rates may be prevalent. That

study will begin this spring and be completed within the next 2 ½ years or by the end of 2006.


We now have a comprehensive mailing list for almost everyone who has ever worked at Spring House and are continuing to update the list when we get new names. We will be mailing information on the cohort mortality investigation to current and former Spring House employees this year.

We will also publish an article defining the brain cancer study and our results in a peer-reviewed journal later this year.


The study was worthwhile and important. We now have a better understanding of the brain cancer cases at Spring House and a scientific basis for believing that these cancers show no statistically significant association with any one risk factor. A prudent next step will be the investigation of all mortalities at the site. It is our firm belief that based on the study findings and review of the current health and safety practices, Spring House is a safe place to work.

In the meantime, we will continue to share information with you as it becomes available. As we have announced before, we are available to answer your questions, discuss your concerns and listen to your suggestions. Please also feel free to talk with Dr. Jeff Erinoff at 215-619-5351.

Sincerely,



Arvind V. Carpenter, D.PH, D.D.S
Director of Epidemiology and
Global EHS and Sustainable Development



David E. Greenley, Ph.D.
Director, Technical Operations and
Spring House Facility Manager